ImClone To Pay Abbott $17.5M To Settle Erbitux Suits
ImClone Systems Inc. has agreed to pay Abbott Laboratories $17.5 million to settle a patent dispute over the cancer drug Erbitux and to withdraw a countersuit accusing Abbott of concealing information...To view the full article, register now.
Already a subscriber? Click here to view full article